Better Therapeutics is a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases. Better was founded upon the realization that nearly half a trillion dollars are spent each year treating the symptoms or effects of cardiometabolic diseases while little is being done to address the behaviors that cause them.
The cognitive behavioral therapy delivered by Better Therapeutics’ PDT is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs.
We have validated the clinical effectiveness of our software in peer-reviewed and published clinical trials, and are beginning to commercialize with private health insurers while pursuing FDA clearance for our first indication in diabetes.
Led by an experienced team of biotechnology executives with funding from top-tier industry investors, Better went public through a merger with SPAC Mountain Crest Acquisition Corp. (NASDAQ: MCAD) during the fall of 2021.
We operate as a fully distributed company combining remote work with periodic team and all-hands in-person meetings. We are headquartered in San Francisco, CA and have team members located in 22 states across the country. For more information, please visit our website at www.bettertx.com